Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A GLP-1 receptor agonist with a strong human trial record and multiple FDA approvals for type 2 diabetes and chronic weight management.
What it is & how it works
What it is
Semaglutide is a GLP-1 receptor agonist — a molecule that mimics glucagon-like peptide-1, a hormone your gut releases after eating. It is one of the most-studied compounds covered here, with several FDA-approved products.
How it works
By activating GLP-1 receptors, semaglutide enhances glucose-dependent insulin release, slows gastric emptying, and acts on appetite signaling in the brain. The net effect in trials is improved blood-sugar control and, at higher doses, meaningful weight reduction.
The evidence
This is the high end of the evidence spectrum: large randomized controlled trials (the SUSTAIN and STEP programs) plus cardiovascular outcomes data. That’s a different tier of proof than the preclinical research peptides elsewhere in this encyclopedia — and it’s why approved semaglutide should be used as a prescription drug, under clinical care.
What it's discussed & studied for
- Type 2 diabetes (approved)
- Chronic weight management (approved)
- Cardiovascular risk reduction in specific populations
Discussion of a use is not a claim that it works or is approved.
Research status
Approved by the FDA and supported by large randomized controlled trials (the STEP and SUSTAIN programs).
Evidence quality
High, relative to most compounds in this encyclopedia: large, randomized, controlled human trials with cardiovascular outcome data.
Dosing discussion
Approved products use defined titration schedules to manage gastrointestinal side effects. Dosing should come from a prescribing clinician and the product label — not from community sources.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Common effects are gastrointestinal (nausea, etc.). Labeled warnings exist (including a boxed thyroid C-cell tumor warning based on rodent studies). This is a prescription drug; use it under medical supervision.
Sourcing literacy
Approved semaglutide is a prescription product. Compounded or gray-market 'semaglutide' carries identity, dosing, and purity risks and is a frequent subject of FDA warnings.
Selected literature
FAQ
Is semaglutide FDA-approved?
Yes — for type 2 diabetes and, in a higher-dose product, for chronic weight management, with additional cardiovascular indications in specific groups.
How is it different from tirzepatide?
Semaglutide targets the GLP-1 receptor; tirzepatide is a dual GLP-1/GIP agonist. Head-to-head and trial data differ — see the tirzepatide page.